Dostinex tab has been approved for the treatment of hyperprolactinemic disorders, either idiopathic or as a result of pituitary adenomas (tumors).
In clinical trials of approximately 450 subjects, Dostinex Price was compared with bromocriptine in the treatment of hyperprolactinemia. At eight-week, double-blind, prolactin levels returned in 77% of Dostinex treatments (0.5mg twice weekly) compared to 59% of those treated with bromocriptine (2.5 mg twice-daily). Recovery from menses occurred in 77% of women treated with Dostinex, compared to 70% of those treated with bromocriptine.
Of the subjects with galactorrhea (breast milk release), the symptoms disappeared in 73% of those treated with Dostinex, compared with 56% of the 231 people taking bromocriptine.
Dostinex Side Effects
Clinical studies have also shown a lower safety of Dostinex compared to positive for bromocriptine. Two percent of the 221 doses of Dostinex eliminated therapy due to side effects during the eight-week study period, compared to the percentage of 231 the bromocriptine was taken.
Nausea is the most common side effect of both medications. During the eight-week, double-blind trial, 29% of subjects experienced nausea with Dostinex compared with 43% of those who took bromocriptine.
Dostinex tab is contraindicated for subjects who cannot tolerate hypertension or have known adverse reactions to ergot derivatives.
Hyperprolactinemia is usually caused by the cancers of the pituitary gland that causes prolactin production, a hormone that regulates lactation. Physicians treat from 70,000 to 100,000 patients with the disease each year, most of whom are women. It most commonly affects women between the ages of 20 and 50 and can cause menstrual cycle loss, excessive breast milk and pregnancy. In men, the condition can lead to reduced libido and impotence.